FBIOP · Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow FBIOP by emailGet an email when FBIOP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FBIOP, unsubscribe in one click. Privacy
📣 What FBIOP Says Is Next
fourth quarter of 2026 · “A clinical trial evaluating MB-109, a combination CAR T cell therapy and oncolytic virus, is anticipated to initiate in the fourth quarter of 2026 for patients with IL13Rα2-positive recurrent glioblastoma and high-grade astrocytoma.”
Company press release, Aug 13, 2026 · SEC filing
in 2026 · “Avenue anticipates meeting with the FDA in 2026 to discuss and align on the design of a potential single pivotal trial for ATX-04 for Pompe disease. Financial Results: ”
Company press release, May 14, 2026 · SEC filing
in 2026 · “Avenue anticipates meeting with the FDA in 2026 to discuss and align on the design of a potential single pivotal trial for ATX-04 for Pompe disease.”
Company press release, Mar 31, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full FBIOP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FBIOP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.